CIBC downgraded Valeant Pharmaceuticals (NYSE: VRX) from Sector ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Downgrades

Jefferies Cuts Price Target to $224 Following Valeant Pharma (VRX) 3Q EPS Beat October 20, 2015 10:22 AM Mizuho Securities Remains Neutral After Valeant Pharma (VRX) Reports 2c EPS Beat October 20, 2015 6:46 AM BMO Capital Cuts Price target on Valeant Pharma (VRX) Following Poor 3Q Legacy Business Performance October 20, 2015 6:42 AM Valeant CEO sees new drug pricing environment aheadOctober 19, 2015 6:13 AM Valeant Pharma (VRX) Reports Q3 EPS of $0.14; Boosts FY15 EPS OutlookOctober 19, 2015 6:10 AM Valeant Pharmaceuticals Reports Third Quarter 2015 Financial ResultsOctober 19, 2015 6:00 AM